Table 4.
Effect of Tdap booster dosing on 0–1 year incidence
| Scenario | Without Tdap11-year booster | With Tdap11-year booster | Difference in incidence with andwithout Tdap 11-year booster (%) | |||
|---|---|---|---|---|---|---|
| Inc1 | Inc2 | Inc1 | Inc2 | Inc1 | Inc1 + Inc2 | |
| CP1A-SDI | 6·6 | 16·7 | 6·4 | 16·3 | 2·8 | 2·6 |
| CP1A-MDI | 7·3 | 15·0 | 7·2 | 14·7 | 2·1 | 2·2 |
| CP1A-LDI | 7·3 | 12·4 | 7·0 | 12·0 | 3·3 | 3·7 |
| CP1B-SDI | 7·4 | 21·5 | 7·3 | 21·3 | 2·2 | 1·5 |
| CP1B-MDI | 8·8 | 19·3 | 8·7 | 19·1 | 1·0 | 1·1 |
| CP1B-LDI | 9·0 | 16·5 | 8·9 | 16·3 | 1·2 | 1·4 |
| CP2-SDI | 13·6 | 19·6 | 13·2 | 19·2 | 2·4 | 2·4 |
| CP2-MDI | 10·2 | 13·8 | 9·9 | 13·4 | 3·1 | 3·0 |
| CP2-LDI | 7·8 | 9·9 | 7·5 | 9·4 | 4·0 | 4·1 |
CP, Contact parameter; SDI, short duration immunity; MDI, medium duration immunity; LDI, long duration immunity.
Incidences are given in cases/year per 100 000 population.